Caroline Boulton, who leads the drug development efforts of Novartis in malaria, is confident that the disease can be eliminated in the decades to come. But, she cautions, it will take concerted and coordinated political and industrial action to reach this goal, including training healthcare professionals in malaria endemic regions, and, above all, continued efforts to innovate. With three drug candidates in its pipeline, Novartis is set to play a major role in making malaria history.

Published on 13/09/2021